AgeX Therapeutics Competitors

Medicenna Therapeutics (NASDAQ:MDNA) and AgeX Therapeutics (NYSE:AGE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Profitability

This table compares Medicenna Therapeutics and AgeX Therapeutics' net margins, return on equity and return on assets.

Risk and Volatility

Medicenna Therapeutics has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500. Comparatively, AgeX Therapeutics has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500.

Insider and Institutional Ownership

3.9% of Medicenna Therapeutics shares are held by institutional investors. Comparatively, 13.2% of AgeX Therapeutics shares are held by institutional investors. 3.3% of AgeX Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Medicenna Therapeutics and AgeX Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Medicenna Therapeutics has higher earnings, but lower revenue than AgeX Therapeutics.

Analyst Ratings

This is a summary of current ratings and target prices for Medicenna Therapeutics and AgeX Therapeutics, as reported by MarketBeat.

Medicenna Therapeutics presently has a consensus price target of $10.00, indicating a potential upside of 171.00%. Given Medicenna Therapeutics' higher probable upside, equities analysts clearly believe Medicenna Therapeutics is more favorable than AgeX Therapeutics.

Summary

Medicenna Therapeutics beats AgeX Therapeutics on 6 of the 11 factors compared between the two stocks.

Sol-Gel Technologies (NASDAQ:SLGL) and AgeX Therapeutics (NYSE:AGE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.

Insider & Institutional Ownership

30.9% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 13.2% of AgeX Therapeutics shares are held by institutional investors. 3.3% of AgeX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Sol-Gel Technologies and AgeX Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

AgeX Therapeutics has lower revenue, but higher earnings than Sol-Gel Technologies.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Sol-Gel Technologies and AgeX Therapeutics, as reported by MarketBeat.

Sol-Gel Technologies presently has a consensus target price of $21.00, indicating a potential upside of 120.13%. Given Sol-Gel Technologies' higher possible upside, research analysts plainly believe Sol-Gel Technologies is more favorable than AgeX Therapeutics.

Profitability

This table compares Sol-Gel Technologies and AgeX Therapeutics' net margins, return on equity and return on assets.

Volatility and Risk

Sol-Gel Technologies has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Comparatively, AgeX Therapeutics has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500.

Summary

Sol-Gel Technologies beats AgeX Therapeutics on 7 of the 12 factors compared between the two stocks.

AgeX Therapeutics (NYSE:AGE) and Xeris Pharmaceuticals (NASDAQ:XERS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for AgeX Therapeutics and Xeris Pharmaceuticals, as reported by MarketBeat.com.

Xeris Pharmaceuticals has a consensus target price of $13.00, indicating a potential upside of 300.00%. Given Xeris Pharmaceuticals' higher possible upside, analysts clearly believe Xeris Pharmaceuticals is more favorable than AgeX Therapeutics.

Earnings and Valuation

This table compares AgeX Therapeutics and Xeris Pharmaceuticals' revenue, earnings per share and valuation.

AgeX Therapeutics has higher earnings, but lower revenue than Xeris Pharmaceuticals.

Risk and Volatility

AgeX Therapeutics has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, Xeris Pharmaceuticals has a beta of 2.22, indicating that its share price is 122% more volatile than the S&P 500.

Profitability

This table compares AgeX Therapeutics and Xeris Pharmaceuticals' net margins, return on equity and return on assets.

Insider and Institutional Ownership

13.2% of AgeX Therapeutics shares are held by institutional investors. Comparatively, 69.3% of Xeris Pharmaceuticals shares are held by institutional investors. 3.3% of AgeX Therapeutics shares are held by company insiders. Comparatively, 6.1% of Xeris Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Xeris Pharmaceuticals beats AgeX Therapeutics on 10 of the 12 factors compared between the two stocks.

AgeX Therapeutics (NYSE:AGE) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Earnings & Valuation

This table compares AgeX Therapeutics and Eton Pharmaceuticals' gross revenue, earnings per share and valuation.

AgeX Therapeutics has higher revenue and earnings than Eton Pharmaceuticals.

Analyst Ratings

This is a summary of current ratings and target prices for AgeX Therapeutics and Eton Pharmaceuticals, as provided by MarketBeat.

Eton Pharmaceuticals has a consensus price target of $12.00, indicating a potential upside of 51.71%. Given Eton Pharmaceuticals' higher probable upside, analysts clearly believe Eton Pharmaceuticals is more favorable than AgeX Therapeutics.

Insider and Institutional Ownership

13.2% of AgeX Therapeutics shares are owned by institutional investors. Comparatively, 29.1% of Eton Pharmaceuticals shares are owned by institutional investors. 3.3% of AgeX Therapeutics shares are owned by company insiders. Comparatively, 12.9% of Eton Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares AgeX Therapeutics and Eton Pharmaceuticals' net margins, return on equity and return on assets.

Risk and Volatility

AgeX Therapeutics has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Comparatively, Eton Pharmaceuticals has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500.

Summary

Eton Pharmaceuticals beats AgeX Therapeutics on 8 of the 12 factors compared between the two stocks.

AgeX Therapeutics (NYSE:AGE) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Valuation & Earnings

This table compares AgeX Therapeutics and Iterum Therapeutics' gross revenue, earnings per share and valuation.

AgeX Therapeutics has higher revenue and earnings than Iterum Therapeutics.

Volatility and Risk

AgeX Therapeutics has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for AgeX Therapeutics and Iterum Therapeutics, as provided by MarketBeat.com.

Iterum Therapeutics has a consensus price target of $3.25, indicating a potential upside of 203.74%. Given Iterum Therapeutics' higher probable upside, analysts plainly believe Iterum Therapeutics is more favorable than AgeX Therapeutics.

Insider & Institutional Ownership

13.2% of AgeX Therapeutics shares are owned by institutional investors. Comparatively, 10.1% of Iterum Therapeutics shares are owned by institutional investors. 3.3% of AgeX Therapeutics shares are owned by company insiders. Comparatively, 22.1% of Iterum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares AgeX Therapeutics and Iterum Therapeutics' net margins, return on equity and return on assets.

Summary

Iterum Therapeutics beats AgeX Therapeutics on 8 of the 12 factors compared between the two stocks.

AgeX Therapeutics (NYSE:AGE) and Checkpoint Therapeutics (NASDAQ:CKPT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Valuation & Earnings

This table compares AgeX Therapeutics and Checkpoint Therapeutics' gross revenue, earnings per share and valuation.

AgeX Therapeutics has higher revenue and earnings than Checkpoint Therapeutics.

Volatility and Risk

AgeX Therapeutics has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, Checkpoint Therapeutics has a beta of 1.66, indicating that its share price is 66% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for AgeX Therapeutics and Checkpoint Therapeutics, as provided by MarketBeat.com.

Checkpoint Therapeutics has a consensus price target of $17.6667, indicating a potential upside of 603.85%. Given Checkpoint Therapeutics' higher probable upside, analysts plainly believe Checkpoint Therapeutics is more favorable than AgeX Therapeutics.

Insider & Institutional Ownership

13.2% of AgeX Therapeutics shares are owned by institutional investors. Comparatively, 18.8% of Checkpoint Therapeutics shares are owned by institutional investors. 3.3% of AgeX Therapeutics shares are owned by company insiders. Comparatively, 7.8% of Checkpoint Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares AgeX Therapeutics and Checkpoint Therapeutics' net margins, return on equity and return on assets.

Summary

Checkpoint Therapeutics beats AgeX Therapeutics on 8 of the 12 factors compared between the two stocks.